1
|
Castro G, Cobo M, Rodríguez I. Identification of hazardous organic compounds in e-waste plastic using non-target and suspect screening approaches. Chemosphere 2024; 356:141946. [PMID: 38604518 DOI: 10.1016/j.chemosphere.2024.141946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 04/05/2024] [Accepted: 04/06/2024] [Indexed: 04/13/2024]
Abstract
End-of-life electric and electronic devices stand as one of the fastest growing wastes in the world and, therefore, a rapidly escalating global concern. A relevant fraction of these wastes corresponds to polymeric materials containing a plethora of chemical additives. Some of those additives fall within the category of hazardous organic compounds (HOCs). Despite the significant advances in the capabilities of analytical methods, the comprehensive characterization of WEEE plastic remains as a challenge. This research strives to identify the primary additives within WEEE polymers by implementing a non-target and suspect screening approach. Gas chromatography coupled to time-of-flight mass spectrometry (GC-QTOF-MS), using electron ionization (EI), was applied for the detection and identification of more than 300 substances in this matrix. A preliminary comparison was carried out with nominal resolution EI-MS spectra contained in the NIST17 library. BPA, flame retardants, UV-filters, PAHs, and preservatives were among the compounds detected. Fifty-one out of 300 compounds were confirmed by comparison with authentic standards. The study establishes a comprehensive database containing m/z ratios and accurate mass spectra of characteristic compounds, encompassing HOCs. Semi-quantification of the predominant additives was conducted across 48 WEEE samples collected from handling and dismantling facilities in Galicia. ABS plastic demonstrated the highest median concentrations, ranging from 0.154 to 4456 μg g-1, being brominated flame retardants and UV filters, the families presenting the highest concentrations. Internet router devices revealed the highest concentrations, containing a myriad of HOCs, such as tetrabromobisphenol A (TBBPA), tribromophenol (TBrP), triphenylphosphate (TPhP), tinuvin P and bisphenol A (BPA), most of which are restricted in Europe.
Collapse
Affiliation(s)
- G Castro
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute for Research in Chemical and Biological Analysis (IAQBUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
| | - M Cobo
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute for Research in Chemical and Biological Analysis (IAQBUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - I Rodríguez
- Department of Analytical Chemistry, Nutrition and Food Sciences, Institute for Research in Chemical and Biological Analysis (IAQBUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| |
Collapse
|
2
|
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024; 35:77-90. [PMID: 37879444 DOI: 10.1016/j.annonc.2023.10.117] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 10/11/2023] [Accepted: 10/12/2023] [Indexed: 10/27/2023] Open
Abstract
BACKGROUND Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. RESULTS All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death 0.55 and 0.58, respectively). Predominant adverse events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and MET-related toxicities. Amivantamab-chemotherapy had lower rates of hematologic AEs than amivantamab-lazertinib-chemotherapy. CONCLUSIONS Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.
Collapse
Affiliation(s)
- A Passaro
- Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
| | - J Wang
- Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Y Wang
- Department of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - S-H Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - B Melosky
- British Columbia Cancer Agency, Vancouver, Canada
| | - J-Y Shih
- Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
| | - J Wang
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - K Azuma
- Kurume University School of Medicine, Kurume, Japan
| | - O Juan-Vidal
- Hospital Universitari i Politécnic La Fe, Valencia, Spain
| | - M Cobo
- Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain
| | - E Felip
- Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - N Girard
- Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, France
| | - A B Cortot
- University of Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - R Califano
- Department of Medical Oncology, Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, UK
| | - F Cappuzzo
- IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - S Owen
- Department of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada
| | - S Popat
- Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - J-L Tan
- Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - J Salinas
- Centro de Especialidades Medicas Ambulatorias e Investigación Clínica, Córdoba, Argentina
| | - P Tomasini
- Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - R D Gentzler
- Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA
| | - W N William
- Centro Oncológico BP, Beneficência Portuguesa de São Paulo, and Grupo Oncoclínicas, São Paulo, Brazil
| | - K L Reckamp
- Cedars-Sinai Medical Center, Los Angeles, USA
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan
| | | | - D M Kowalski
- Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - A Bearz
- Medical Oncology, Centro di Riferimento Oncologico-CRO, Aviano, Italy
| | - M MacKean
- Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
| | - P Barala
- Janssen Research & Development, Spring House, PA, USA
| | - A B Bourla
- Janssen Research & Development, Raritan, NJ, USA
| | - A Girvin
- Janssen Research & Development, Spring House, PA, USA
| | - J Greger
- Janssen Research & Development, Spring House, PA, USA
| | - D Millington
- Janssen Research & Development, San Diego, CA, USA
| | - M Withelder
- Janssen Research & Development, Spring House, PA, USA
| | - J Xie
- Janssen Research & Development, Raritan, NJ, USA
| | - T Sun
- Janssen Research & Development, Raritan, NJ, USA
| | - S Shah
- Janssen Research & Development, Spring House, PA, USA
| | - B Diorio
- Janssen Research & Development, Raritan, NJ, USA
| | - R E Knoblauch
- Janssen Research & Development, Spring House, PA, USA
| | - J M Bauml
- Janssen Research & Development, Spring House, PA, USA
| | - R G Campelo
- University Hospital A Coruña, A Coruña, Spain
| | - B C Cho
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
3
|
Cobo M, Menéndez Fernández-Miranda P, Bastarrika G, Lloret Iglesias L. Enhancing radiomics and Deep Learning systems through the standardization of medical imaging workflows. Sci Data 2023; 10:732. [PMID: 37865635 PMCID: PMC10590396 DOI: 10.1038/s41597-023-02641-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 10/12/2023] [Indexed: 10/23/2023] Open
Affiliation(s)
- Miriam Cobo
- Advanced Computing and e-Science Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, Santander, Spain.
| | | | - Gorka Bastarrika
- Clínica Universidad de Navarra, Department of Radiology, Pamplona, Spain
| | - Lara Lloret Iglesias
- Advanced Computing and e-Science Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, Santander, Spain
| |
Collapse
|
4
|
Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol 2023; 34:920-933. [PMID: 37704166 DOI: 10.1016/j.annonc.2023.07.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 07/04/2023] [Accepted: 07/05/2023] [Indexed: 09/15/2023] Open
Abstract
BACKGROUND Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. PATIENTS AND METHODS ATALANTE-1 was a two-step open-label study to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) chemotherapy (CT). Patients with human leukocyte antigen (HLA)-A2-positive advanced NSCLC without actionable alterations, failing sequential or concurrent CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of interim analysis, a decision was taken to prematurely stop the accrual due to coronavirus disease 2019 (COVID-19). Final analysis was carried out in all patients and in the subgroup of patients with ICB secondary resistance defined as failure after ICB monotherapy second line ≥12 weeks. RESULTS Two hundred and nineteen patients were randomized (139 OSE2101, 80 SoC); 118 had secondary resistance to sequential ICB. Overall, median OS non-significantly favored OSE2101 over SoC {hazard ratio (HR) [95% confidence interval (CI)] 0.86 [0.62-1.19], P = 0.36}. In the secondary resistance subgroup, OSE2101 significantly improved median OS versus SoC [11.1 versus 7.5 months; HR (95% CI) 0.59 (0.38-0.91), P = 0.017], and significantly improved post-progression survival (HR 0.46, P = 0.004), time to Eastern Cooperative Oncology Group (ECOG) performance status deterioration (HR 0.43, P = 0.006) and Quality of Life Questionnaire Core 30 (QLQ-C30) global health status compared to SoC (P = 0.045). Six-month disease control rates and progression-free survival were similar between groups. Grade ≥3 adverse effects occurred in 11.4% of patients with OSE2101 and 35.1% in SoC (P = 0.002). CONCLUSIONS In HLA-A2-positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to CT. Further evaluation in this population is warranted.
Collapse
Affiliation(s)
- B Besse
- Paris-Saclay University, Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France.
| | - E Felip
- Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona
| | - R Garcia Campelo
- Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Biomedical Research Institute, INIBIC, A Coruña
| | - M Cobo
- Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain
| | - C Mascaux
- Pneumology Department, Hôpitaux Universitaires de Strasbourg-Nouvel Hôpital Civil, Strasbourg
| | - A Madroszyk
- Medical Oncology Department, IPC-Institut Paoli-Calmettes, Marseille, France
| | - F Cappuzzo
- Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - W Hilgers
- Medical Oncology Department, Sainte Catherine Cancer Center, Avignon, France
| | - G Romano
- Medical Oncology Department, Ospedale Vito Fazzi-ASL Lecce, Lecce, Italy
| | - F Denis
- Medical Oncology Department, Institut Inter-Régional de Cancérologie Jean Bernard-Elsan, Le Mans, France
| | - S Viteri
- Medical Oncology Department, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Grupo Quironsalud, Barcelona, Spain
| | - D Debieuvre
- Pneumology Department, Groupe Hospitalier de la Région Mulhouse Sud Alsace, Mulhouse, France
| | - D Galetta
- Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari
| | - E Baldini
- Oncology Department, Ospedale San Luca, Lucca, Italy
| | - M Razaq
- Oncology Department, Stephenson Cancer Center, Oklahoma City, USA
| | - G Robinet
- Oncology Department, Centre Hospitalier Régional Universitaire Morvan, Brest, France
| | - M Maio
- Department of Oncology, University of Siena and Center for Immuno-Oncology, University Hospital, Siena
| | - A Delmonte
- Thoracic Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy
| | - B Roch
- Thoracic Oncology Unit, Montpellier University, University Hospital of Montpellier, Montpellier
| | - P Masson
- Pneumology Department, Centre Hospitalier de Cholet, Cholet, France
| | - W Schuette
- Medical Oncology Department, Hospital Martha-Maria Halle-Doelau, Halle, Germany
| | - A Zer
- Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
| | - J Remon
- Paris-Saclay University, Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France
| | - D Costantini
- Medical Development Department, OSE Immunotherapeutics, Paris, France
| | - B Vasseur
- Medical Development Department, OSE Immunotherapeutics, Paris, France
| | - R Dziadziuszko
- Oncology and Radiotherapy Department and Early Phase Clinical Trials Centre, Medical University of Gdansk, Gdansk, Poland
| | - G Giaccone
- Meyer Cancer Center, Weill Cornell Medicine, New York, USA
| |
Collapse
|
5
|
Cobo M, Pérez-Rojas F, Gutiérrez-Rodríguez C, Heredia I, Maragaño-Lizama P, Yung-Manriquez F, Iglesias LL, Vega JA. Publisher Correction: Novel deep learning method for coronary artery tortuosity detection through coronary angiography. Sci Rep 2023; 13:12050. [PMID: 37491442 PMCID: PMC10368645 DOI: 10.1038/s41598-023-39135-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023] Open
Affiliation(s)
- Miriam Cobo
- Advanced Computing and e-Science Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain.
| | - Francisco Pérez-Rojas
- Facultad de Medicina, Universidad Católica del Maule, Talca, Chile
- Departamento de Morfología y Biología Celular, Grupo de Investigación SINPOS, Universidad de Oviedo, 33006, Oviedo, Principality of Asturias, Spain
| | | | - Ignacio Heredia
- Advanced Computing and e-Science Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain
| | | | | | - Lara Lloret Iglesias
- Advanced Computing and e-Science Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain
| | - José A Vega
- Facultad de Medicina, Universidad Católica del Maule, Talca, Chile
- Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile
| |
Collapse
|
6
|
Cobo M, Pérez-Rojas F, Gutiérrez-Rodríguez C, Heredia I, Maragaño-Lizama P, Yung-Manriquez F, Lloret Iglesias L, Vega JA. Novel deep learning method for coronary artery tortuosity detection through coronary angiography. Sci Rep 2023; 13:11137. [PMID: 37429940 PMCID: PMC10333289 DOI: 10.1038/s41598-023-37868-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 06/28/2023] [Indexed: 07/12/2023] Open
Abstract
Coronary artery tortuosity is usually an undetected condition in patients undergoing coronary angiography. This condition requires a longer examination by the specialist to be detected. Yet, detailed knowledge of the morphology of coronary arteries is essential for planning any interventional treatment, such as stenting. We aimed to analyze coronary artery tortuosity in coronary angiography with artificial intelligence techniques to develop an algorithm capable of automatically detecting this condition in patients. This work uses deep learning techniques, in particular, convolutional neural networks, to classify patients into tortuous or non-tortuous based on their coronary angiography. The developed model was trained both on left (Spider) and right (45°/0°) coronary angiographies following a fivefold cross-validation procedure. A total of 658 coronary angiographies were included. Experimental results demonstrated satisfactory performance of our image-based tortuosity detection system, with a test accuracy of (87 ± 6)%. The deep learning model had a mean area under the curve of 0.96 ± 0.03 over the test sets. The sensitivity, specificity, positive predictive values, and negative predictive values of the model for detecting coronary artery tortuosity were (87 ± 10)%, (88 ± 10)%, (89 ± 8)%, and (88 ± 9)%, respectively. Deep learning convolutional neural networks were found to have comparable sensitivity and specificity with independent experts' radiological visual examination for detecting coronary artery tortuosity for a conservative threshold of 0.5. These findings have promising applications in the field of cardiology and medical imaging.
Collapse
Affiliation(s)
- Miriam Cobo
- Advanced Computing Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain.
| | - Francisco Pérez-Rojas
- Grupo de Investigación MEXPA, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile
- Grupo de Investigación SINPOS, Departamento de Morfología y Biología Celular, Universidad de Oviedo, 3306, Oviedo, Principality of Asturias, Spain
| | | | - Ignacio Heredia
- Advanced Computing Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain
| | | | | | - Lara Lloret Iglesias
- Advanced Computing Research Group, Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005, Santander, Cantabria, Spain
| | - José A Vega
- Grupo de Investigación MEXPA, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile
- Grupo de Investigación SINPOS, Departamento de Morfología y Biología Celular, Universidad de Oviedo, 3306, Oviedo, Principality of Asturias, Spain
| |
Collapse
|
7
|
Aguilar A, Cobo M, Azkarate A, Calles A, Gonzalez-Cao M, Cantero A, Terrasa J, Álvarez R, Molina M, Rosell R. 79TiP Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00333-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
8
|
Romero A, Serna R, Nadal E, Larriba JG, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Fernandez AG, Calvo V, Insa A, Ponce S, Reguart N, De Castro J, Massutí B, Palmero R, Aguado de la Rosa C, Mosquera J, Cobo M, Aguilar A, Vivanco GL, Camps C, Trancho FH, Castro RL, Moran T, Barneto I, Rodríguez-Abreu D, Cruz A, Provencio M. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Aguilar A, Cobo M, Azkárate A, Calles A, Molina M, Rosell R. EP08.02-011 Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Provencio-pulla M, Ortega A, Coves J, Franco F, Marsé R, Dómine M, Guirado M, Carcereny E, Fernández N, Martinez E, Blanco R, León L, Sánchez J, Sullivan I, Cobo M, Sánchez A, Massutí B. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Cobo M, Heredia I, Aguilar F, Lloret Iglesias L, García D, Bartolomé B, Moreno-Arribas MV, Yuste S, Pérez-Matute P, Motilva MJ. Artificial intelligence to estimate wine volume from single-view images. Heliyon 2022; 8:e10557. [PMID: 36119876 PMCID: PMC9475323 DOI: 10.1016/j.heliyon.2022.e10557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 03/08/2022] [Accepted: 09/01/2022] [Indexed: 12/03/2022] Open
Abstract
In this paper, we present a method to determine the volume of wine in different types of glass liquid containers from a single-view image. The proposed model predicts red wine volume from a photograph of the glass containing the wine. Experimental results demonstrated satisfactory performance of our image-based wine measurement system, with a Mean Absolute Error lower than 10mL. To train and evaluate our system, we introduced the WineGut_BrainUp dataset, a new dataset of glasses of wine that contains 24305 laboratory images, including a wide range of containers, volumes of wine, backgrounds, object distances, angles and lightning, with or without calibration object. The proposed methodology is a suitable analytical tool for automate measurement of red wine volume. Indeed, it has potential real life applications in diet monitoring and wine consumption studies.
Collapse
Affiliation(s)
- Miriam Cobo
- Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005 Santander (Cantabria), Spain
- Corresponding author.
| | - Ignacio Heredia
- Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005 Santander (Cantabria), Spain
| | - Fernando Aguilar
- Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005 Santander (Cantabria), Spain
| | - Lara Lloret Iglesias
- Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005 Santander (Cantabria), Spain
| | - Daniel García
- Institute of Physics of Cantabria (IFCA), CSIC - UC, 39005 Santander (Cantabria), Spain
| | - Begoña Bartolomé
- Institute of Food Science Research (CIAL), CSIC-UAM, 28049 Madrid, Spain
| | | | - Silvia Yuste
- Institute of Grapevine and Wine Sciences (ICVV), CSIC-University of La Rioja-Government of La Rioja, 26007 Logroño (La Rioja), Spain
| | | | - Maria-Jose Motilva
- Institute of Grapevine and Wine Sciences (ICVV), CSIC-University of La Rioja-Government of La Rioja, 26007 Logroño (La Rioja), Spain
| |
Collapse
|
12
|
Massutí B, Nadal E, Camps C, Carcereny E, Cobo M, Domine M, Garcia-Campelo M, Gonzalez-Larriba J, Guirado M, Hernando-Trancho F, Rodriguez-Abreu D, Sanchez A, Sullivan I, Provencio M. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
13
|
Provencio M, Serna R, Nadal E, Glez Larriba J, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Garcia Benito C, Calvo V, Insa A, Ponce S, Reguart N, De Castro J, Massutí B, Palmero R, Aguado de la Rosa C, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, Hernando Trancho F, López Castro R, Moran T, Barneto I, Rodríguez-Abreu D, Romero A. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
14
|
Rodríguez-Abreu D, Cobo M, García-Román S, Viteri-Ramírez S, Jordana-Ariza N, García-Peláez B, Reguart N, Aguilar A, Codony-Servat J, Drozdowskyj A, Molina-Vila MA, d'Hondt E, Rosell R. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. Lung Cancer 2021; 164:8-13. [PMID: 34971901 DOI: 10.1016/j.lungcan.2021.12.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/10/2021] [Accepted: 12/20/2021] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Combination of anti-EGFR monoclonal antibodies or immune checkpoint inhibitors with TKIs has shown minimal benefit in EGFR mutant (EGFR-mut) NSCLC patients. Consequently, new combination approaches are needed. PATIENTS AND METHODS The EPICAL was a single arm, phase 1b study to evaluate safety, tolerability and anti-tumor activity of first line afatinib combined with anti-EGF vaccination in advanced EGFR-mut patients. EGFR status and mutations in liquid biopsies were determined by reverse transcriptase-polymerase chain reaction; serum biomarkers by ELISA and Western blotting analysis. RESULTS The assay enrolled 23 patients, 21 completed the anti-EGF immunization phase. Treatment was well tolerated and no serious adverse events (SAEs) related to the anti-EGF vaccine were reported. Objective response and disease control rates were 78.3% (95%CI = 53.6-92.5) and 95.7% (95%CI = 78.1-99.9), respectively. After a median follow-up of 24.2 months, median progression-free survival (PFS) was 14.8 months (95% CI = 9.5-20.1) and median overall survival (OS) 26.9 months (95% CI = 23.0-30.8). Among the 21 patients completing the immunization phase, PFS was 17.5 months (95% CI = 12.0-23.0) and OS 26.9 months (95% CI = 24.6-NR). At the end of the immunization phase, all 21 patients showed high serum titers of anti-EGF antibodies, while EGF levels had decreased significantly. Finally, treatment with fully immunized patient's sera inhibited the EGFR pathway in tumor cells growing in vitro. CONCLUSIONS Combination treatment with an anti-EGF vaccine is well tolerated; induces a sustained immunogenic effect and might enhance the clinical efficacy of EGFR TKIs.
Collapse
Affiliation(s)
- D Rodríguez-Abreu
- Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - M Cobo
- Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - S García-Román
- Laboratorio de Oncología, Pangaea Oncology, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | | | - N Jordana-Ariza
- Laboratorio de Oncología, Pangaea Oncology, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | - B García-Peláez
- Laboratorio de Oncología, Pangaea Oncology, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | - N Reguart
- Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clínic, Barcelona, Spain
| | - A Aguilar
- Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | - J Codony-Servat
- Laboratorio de Oncología, Pangaea Oncology, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | - A Drozdowskyj
- Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain
| | - M A Molina-Vila
- Laboratorio de Oncología, Pangaea Oncology, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain.
| | | | - R Rosell
- Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo Quirón Salud, Barcelona, Spain.
| |
Collapse
|
15
|
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open 2021; 6:100345. [PMID: 34864501 PMCID: PMC8649668 DOI: 10.1016/j.esmoop.2021.100345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
| | - T-E Ciuleanu
- Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | - M Cobo
- Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - M Schenker
- Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania
| | - B Zurawski
- Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland
| | - J Menezes
- Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
| | - E Richardet
- Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina
| | - J Bennouna
- Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - O Juan-Vidal
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
| | - A Alexandru
- Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania
| | - H Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
| | - A Lingua
- Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina
| | - F Reyes
- Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile
| | - P-J Souquet
- Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France
| | - P De Marchi
- Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil
| | - C Martin
- Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - M Pérol
- Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France
| | - A Scherpereel
- Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France
| | - S Lu
- Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China
| | - L Paz-Ares
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain
| | - D P Carbone
- Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - A Memaj
- Bristol Myers Squibb, Princeton, USA
| | | | - X Zhang
- Bristol Myers Squibb, Princeton, USA
| | - P Tran
- Bristol Myers Squibb, Princeton, USA
| | - T John
- Department of Medical Oncology, Austin Hospital, Heidelberg, Australia
| |
Collapse
|
16
|
Cho B, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E, Patil N, Huang M, Zhang Z, Wen X, Mendus D, Hoang T, Meng R, Johnson M. LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.217] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
17
|
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 2021; 6:100273. [PMID: 34607285 PMCID: PMC8493593 DOI: 10.1016/j.esmoop.2021.100273] [Citation(s) in RCA: 89] [Impact Index Per Article: 29.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/11/2021] [Accepted: 08/23/2021] [Indexed: 11/02/2022] Open
Abstract
BACKGROUND To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS With a 2-year minimum follow-up, nivolumab plus ipilimumab with two cycles of chemotherapy provided durable efficacy benefits over chemotherapy with a manageable safety profile and remains an efficacious first-line treatment of advanced non-small-cell lung cancer.
Collapse
Affiliation(s)
- M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
| | - T-E Ciuleanu
- Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | - M Cobo
- Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - M Schenker
- Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania
| | - B Zurawski
- Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland
| | - J Menezes
- Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
| | - E Richardet
- Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina
| | - J Bennouna
- Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona
| | - O Juan-Vidal
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
| | - A Alexandru
- Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania
| | - H Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
| | - A Lingua
- Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina
| | - F Reyes
- Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile
| | - P-J Souquet
- Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France
| | - P De Marchi
- Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil
| | - C Martin
- Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - M Pérol
- Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France
| | - A Scherpereel
- Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France
| | - S Lu
- Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China
| | - L Paz-Ares
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain
| | - D P Carbone
- Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - A Memaj
- Bristol Myers Squibb, Princeton, USA
| | | | - X Zhang
- Bristol Myers Squibb, Princeton, USA
| | - P Tran
- Bristol Myers Squibb, Princeton, USA
| | - T John
- Department of Medical Oncology, Austin Hospital, Heidelberg, Australia
| |
Collapse
|
18
|
Provencio M, Nadal E, Insa A, Campelo MG, Pereiro D, Domine M, Majem M, Abreu DR, Martinez-Marti A, De Castro J, Cobo M, Vivanco GL, Del Barco E, Bernabé R, Viñolas N, Barneto I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas C, Parra E, Wistuba I, Calvo V, Laza - Briviesca R, Romero A, Massuti B, Cruz A. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Romero A, Nadal E, Serna R, Insa A, Campelo MG, Benito C, Domine M, Majem M, Abreu DR, Martinez-Marti A, De Castro J, Cobo M, Vivanco GL, Del Barco E, Bernabé R, Viñolas N, Barneto I, Viteri S, Pereira E, Royuela A, Casarrubios M, Calvo V, Laza - Briviesca R, Massuti B, Cruz A, Sánchez-Herrero E, Provencio M. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.102] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Calvo V, Carcereny E, Abreu DR, Lopez-Castro R, Guirado M, Camps C, Cobo M, Ortega A, Bernabé R, Massuti B, Mosquera J, Del Barco E, Gonzalez - Larriba J, Bosch - Barrera J, Ojeda CG, Domine M, Juan O, Martínez-Cutillas M, Benítez G, Collazo-Lorduy A, Cucurull M, Provencio M. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Abreu DR, Cobo M, Viteri S, Aguilar-Hernández A, Reguart N, Gonzalez-Cao M, Cabrera-Gálvez C, Moya I, Garcia-Roman S, Codony-Servat J, Peláez BG, Ariza NJ, Molina-Vila M, D'Hondt E, Rosell R. MA03.01 EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Franco F, Carcereny E, Rodríguez-Abreu D, Castro RL, Cobo M, Guirado M, Massuti B, Granados AO, Mosquera J, Juan O, Blasco A, Del Barco E, Caro RB, Bosch-Barrera J, Gonzalez-Larriba J, Sala M, Pérez JT, Oramas J, Estival A, Provencio M. P52.10 Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Felip E, Minotti V, Tan D, Wolf J, Mark M, Boyer M, Hughes B, Bearz A, Moro-Sibilot D, Le X, Vazquez J, Massuti B, Liu N, Hao L, Cheng Y, Tiedt R, Cobo M. P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Borderias T, Gonzalez Lizarbe S, Sanchez J, De Tapia B, Catoya S, Cabrera I, Molina M, Lozano M, Lujan E, Canteli A, Castrillo C, Ruiz Lera M, Sarralde J, Cobo M, Burgos V. Is primary graft failure still a challenge in time of venoarterial extracorporeal membrane oxygenation? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Primary graft failure (PGF) is the leading cause of early mortality after heart transplantation (HT). Its increasing incidence during the last decade may be triggered by the disbalance between receptors and donors that forces the acceptance of suboptimal organs.
Purpose
The aim of our work was to analyse the mechanical circulatory support (MCS) with VA-ECMO in refractory to inotropes PGF and determinate its impact in terms of graft function recovery and survival.
Methods
A retrospective study, analyzing our database of circulatory assist devices between 2009 and 2019. During this period, 252 devices have been implanted (154 ECMOs and 98 ventricular assist devices) and 201 patients have received a HT. We describe the characteristics and evolution of all PGF cases managed with VA-ECMO.
Results
Thirty nine patients (19.4%) developed PGF, defined as significant left, right or biventricular systolic dysfunction in the first 24 hours after HT, associated with hemodynamic instability and requiring high dose of inotropes, intra-aortic balloon pump (IABP) or VA-ECMO. Twenty two cases (56.4%) underwent a VA-ECMO implantation by peripheral cannulation as a bridge to recovery.
The median age was 50.8 (44.3–57.3) years and 77% were male. Biventricular dysfunction was observed in 50% and isolated right ventricular dysfunction in the remaining 50%. At the time of implantation, 59% had IABP and the median of inotropic score was 24 (8–40). Two complications occurred during implantation (one because of a complex vascular access and one due to a malposition of the venous cannula). Anticoagulation was started after a median of 19 hours (10–28; 59% sodic heparin and 36% bivalirudin).
The median support duration was 6.2 days (3–9.2). Graft function was recovered in 90%, making it possible to withdraw the device successfully in 82% of patients. The remaining 18% deceased during the support (2 because of multiorgan failure and 2 due to absence of function recovery).The median hospital length of stay was 63 days (33–93) and hospital and 1-year survival was 68.1%.
Conclusion
The support with VA-ECMO allowed graft function recovery in 90% of severe PGF cases, with a similar survival rate to other centres with MCS. In a scenario with a mortality rate superior to 50%, the MCS programs have managed to increase survival, avoid retransplantation in times of donor shortage and handle the use of suboptimal donors with better chances of success.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Borderias
- University Hospital Marques de Valdecilla, Santander, Spain
| | | | - J Sanchez
- University Hospital Marques de Valdecilla, Santander, Spain
| | - B De Tapia
- University Hospital Marques de Valdecilla, Santander, Spain
| | - S Catoya
- University Hospital Marques de Valdecilla, Santander, Spain
| | - I Cabrera
- University Hospital Marques de Valdecilla, Santander, Spain
| | - M Molina
- University Hospital Marques de Valdecilla, Santander, Spain
| | - M Lozano
- University Hospital Marques de Valdecilla, Santander, Spain
| | - E Lujan
- University Hospital Marques de Valdecilla, Santander, Spain
| | - A Canteli
- University Hospital Marques de Valdecilla, Santander, Spain
| | - C Castrillo
- University Hospital Marques de Valdecilla, Santander, Spain
| | - M Ruiz Lera
- University Hospital Marques de Valdecilla, Santander, Spain
| | - J.A Sarralde
- University Hospital Marques de Valdecilla, Santander, Spain
| | - M Cobo
- University Hospital Marques de Valdecilla, Santander, Spain
| | - V Burgos
- University Hospital Marques de Valdecilla, Santander, Spain
| |
Collapse
|
25
|
Shim B, Lee S, de Castro Carpeño J, Chiu CH, Cobo M, Kim H, Ryu J, Tarruella M, Summers Y, Thomas C, Xu Y, Lowy I, Rietschel P. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1583] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
26
|
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Cheng Y, Paz-Ares L, Lu S, John T, Padilla B, Sun X, Moisei A, Yan J, Yuan Y, Blum S, Carbone D. LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2292] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
27
|
Boque C, Antonio M, Hormigo A, Córdoba R, Lavilla E, Barrenetxea C, Cobo M, Fiallo D, Gonzalez Gascon Y Marin I, Jentoff A. EPIDEMIOLOGICAL STUDY ON THE GERIATRIC ASSESSMENT IN PATIENTS WITH HEMATOLOGICAL CANCER: AN UPDATE OF THE REGISTRY OF THE SPANISH GROUP ON HEMATOGERIATRICS. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31170-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
García IR, Sánchez A, Ortega A, Pradera J, Cobo M, Moreno M, Barneto I, Ruiz S, Fernández I, García T, Toscano F, Perez JT. EP1.01-28 Real World Use of Afatinib in NSCLC EGFRm+ Patients Outside Clinical Trials: A FAETT Experience. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, López-Vivanco G, Del Barco E, Bernabe R, Viñolas N, Barneto I, Viteri S, Martorell PM, Jove M, De Juan VC, Massuti B. OA13.05 NADIM Study: Updated Clinical Research and Outcomes. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.480] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Massuti B, Sanchez J, Cobo M, Moran T, Larriba JG, Barneto I, De Castro Carpeno J, Iglesias L, Muñoz M, López-Vivanco G, Isla D, López R, De Las Penas R, Rodriguez-Abreu D, Artal A, Esteban E, Provencio M, Pereira E, Sanchez-Payá J, Rosell R. MA02.01 Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Angelats L, Campelo RG, Bernabe R, Arriola E, Rocha P, De Juan VC, Sais E, Barba A, Viñolas N, Moreno MG, Vilà L, Juan O, Vilariño N, Cobo M, Domine M, Vazquez S, Coves J, Marse-Fabregat R, Gomez AE, Carcereny E. P1.01-93 Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Zeymer U, Ludman P, Danchin N, Kala P, Maggioni AP, Weidinger F, Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy VK, Nedoshivin A, Petronio AS, Roos-Hesselink J, Wallentin L, Zeymer U, Weidinger F, Zeymer U, Danchin N, Ludman P, Sinnaeve P, Kala P, Ferrari R, Maggioni AP, Goda A, Zelveian P, Weidinger F, Karamfilov K, Motovska Z, Zeymer U, Raungaard B, Marandi T, Shaheen SM, Lidon RM, Karjalainen PP, Kereselidze Z, Alexopoulos D, Becker D, Quinn M, Iakobishvili Z, Al-Farhan H, Sadeghi M, Caporale R, Romeo F, Mirrakhimov E, Serpytis P, Erglis A, Kedev S, Balbi MM, Moore AM, Dudek D, Legutko J, Mimoso J, Tatu-Chitoiu G, Stojkovic S, Shlyakhto E, AlHabib KF, Bunc M, Studencan M, Mourali MS, Bajraktari G, Konte M, Larras F, Lefrancq EF, Mekhaldi S, Laroche C, Maggioni AP, Goda A, Shuka N, Pavli E, Tafaj E, Gishto T, Dibra A, Duka A, Gjana A, Kristo A, Knuti G, Demiraj A, Dado E, Hasimi E, Simoni L, Siqeca M, Sisakian H, Hayrapetyan H, Markosyan S, Galustyan L, Arustamyan N, Kzhdryan H, Pepoyan S, Zirkik A, Von Lewinski D, Paetzold S, Kienzl I, Matyas K, Neunteufl T, Nikfardjam M, Neuhold U, Mihalcz A, Glaser F, Steinwender C, Reiter C, Grund M, Hrncic D, Hoppe U, Hammerer M, Hinterbuchner L, Hengstenberg C, Delle Karth G, Lang I, Weidinger F, Winkler W, Hasun M, Kastner J, Havel C, Derntl M, Oberegger G, Hajos J, Adlbrecht C, Publig T, Leitgeb MC, Wilfing R, Jirak P, Ho CY, Puskas L, Schrutka L, Spinar J, Parenica J, Hlinomaz O, Fendrychova V, Semenka J, Sikora J, Sitar J, Groch L, Rezek M, Novak M, Kramarikova P, Stasek J, Dusek J, Zdrahal P, Polasek R, Karasek J, Seiner J, Sukova N, Varvarovsky I, Lazarák T, Novotny V, Matejka J, Rokyta R, Volovar S, Belohlavek J, Motovska Z, Siranec M, Kamenik M, Kralik R, Raungaard B, Ravkilde J, Jensen SE, Villadsen A, Villefrance K, Schmidt Skov C, Maeng M, Moeller K, Hasan-Ali H, Ahmed TA, Hassan M, ElGuindy A, Farouk Ismail M, Ibrahim Abd El-Aal A, El-sayed Gaafar A, Magdy Hassan H, Ahmed Shafie M, Nabil El-khouly M, Bendary A, Darwish M, Ahmed Y, Amin O, AbdElHakim A, Abosaif K, Kandil H, Galal MAG, El Hefny EE, El Sayed M, Aly K, Mokarrab M, Osman M, Abdelhamid M, Mantawy S, Ali MR, Kaky SD, Khalil VA, Saraya MEA, Talaat A, Nabil M, Mounir WM, Mahmoud K, Aransa A, Kazamel G, Anwar S, Al-Habbaa A, Abd el Monem M, Ismael A, Amin Abu-Sheaishaa M, Abd Rabou MM, Hammouda TMA, Moaaz M, Elkhashab K, Ragab T, Rashwan A, Rmdan A, AbdelRazek G, Ebeid H, Soliman Ghareeb H, Farag N, Zaki M, Seleem M, Torki A, Youssef M, AlLah Nasser NA, Rafaat A, Selim H, Makram MM, Khayyal M, Malasi K, Madkour A, Kolib M, Alkady H, Nagah H, Yossef M, Wafa A, Mahfouz E, Faheem G, Magdy Moris M, Ragab A, Ghazal M, Mabrouk A, Hassan M, El-Masry M, Naseem M, Samir S, Marandi T, Reinmets J, Allvee M, Saar A, Ainla T, Vaide A, Kisseljova M, Pakosta U, Eha J, Lotamois K, Sia J, Myllymaki J, Pinola T, Karjalainen PP, Paana T, Mikkelsson J, Ampio M, Tsivilasvili J, Zurab P, Kereselidze Z, Agladze R, Melia A, Gogoberidze D, Khubua N, Totladze L, Metreveli I, Chikovani A, Eitel I, Pöss J, Werner M, Constantz A, Ahrens C, Zeymer U, Tolksdorf H, Klinger S, Sack S, Heer T, Lekakis J, Kanakakis I, Xenogiannis I, Ermidou K, Makris N, Ntalianis A, Katsaros F, Revi E, Kafkala K, Mihelakis E, Diakakis G, Grammatikopoulos K, Voutsinos D, Alexopoulos D, Xanthopoulou I, Mplani V, Foussas S, Papakonstantinou N, Patsourakos N, Dimopoulos A, Derventzis A, Athanasiou K, Vassilikos VP, Papadopoulos C, Tzikas S, Vogiatzis I, Datsios A, Galitsianos I, Koutsampasopoulos K, Grigoriadis S, Douras A, Baka N, Spathis S, Kyrlidis T, Hatzinikolaou H, Kiss RG, Becker D, Nowotta F, Tóth K, Szabó S, Lakatos C, Jambrik Z, Ruzsa J, Ruzsa Z, Róna S, Toth J, Vargane Kosik A, Toth KSB, Nagy GG, Ondrejkó Z, Körömi Z, Botos B, Pourmoghadas M, Salehi A, Massoumi G, Sadeghi M, Soleimani A, Sarrafzadegan N, Roohafza H, Azarm M, Mirmohammadsadeghi A, Rajabi D, Rahmani Y, Siabani S, Najafi F, Hamzeh B, Karim H, Siabani H, Saleh N, Charehjoo H, Zamzam L, Al-Temimi G, Al-Farhan H, Al-Yassin A, Mohammad A, Ridha A, Al-Saedi G, Atabi N, Sabbar O, Mahmood S, Dakhil Z, Yaseen IF, Almyahi M, Alkenzawi H, Alkinani T, Alyacopy A, Kearney P, Twomey K, Iakobishvili Z, Shlomo N, Beigel R, Caldarola P, Rutigliano D, Sublimi Saponetti L, Locuratolo N, Palumbo V, Scherillo M, Formigli D, Canova P, Musumeci G, Roncali F, Metra M, Lombardi C, Visco E, Rossi L, Meloni L, Montisci R, Pippia V, Marchetti MF, Congia M, Cacace C, Luca G, Boscarelli G, Indolfi C, Ambrosio G, Mongiardo A, Spaccarotella C, De Rosa S, Canino G, Critelli C, Caporale R, Chiappetta D, Battista F, Gabrielli D, Marziali A, Bernabò P, Navazio A, Guerri E, Manca F, Gobbi M, Oreto G, Andò G, Carerj S, Saporito F, Cimmino M, Rigo F, Zuin G, Tuccillo B, Scotto di Uccio F, Irace L, Lorenzoni G, Meloni I, Merella P, Polizzi GM, Pino R, Marzilli M, Morrone D, Caravelli P, Orsini E, Mosa S, Piovaccari G, Santarelli A, Cavazza C, Romeo F, Fedele F, Mancone M, Straito M, Salvi N, Scarparo P, Severino P, Razzini C, Massaro G, Cinque A, Gaudio C, Barillà F, Torromeo C, Porco L, Mei M, Iorio R, Nassiacos D, Barco B, Sinagra G, Falco L, Priolo L, Perkan A, Strana M, Bajraktari G, Percuku L, Berisha G, Mziu B, Beishenkulov M, Abdurashidova T, Toktosunova A, Kaliev K, Serpytis P, Serpytis R, Butkute E, Lizaitis M, Broslavskyte M, Xuereb RG, Moore AM, Mercieca Balbi M, Paris E, Buttigieg L, Musial W, Dobrzycki S, Dubicki A, Kazimierczyk E, Tycinska A, Wojakowski W, Kalanska-Lukasik B, Ochala A, Wanha W, Dworowy S, Sielski J, Janion M, Janion-Sadowska A, Dudek D, Wojtasik-Bakalarz J, Bryniarski L, Peruga JZ, Jonczyk M, Jankowski L, Klecha A, Legutko J, Michalowska J, Brzezinski M, Kozmik T, Kowalczyk T, Adamczuk J, Maliszewski M, Kuziemka P, Plaza P, Jaros A, Pawelec A, Sledz J, Bartus S, Zmuda W, Bogusz M, Wisnicki M, Szastak G, Adamczyk M, Suska M, Czunko P, Opolski G, Kochman J, Tomaniak M, Miernik S, Paczwa K, Witkowski A, Opolski MP, Staruch AD, Kalarus Z, Honisz G, Mencel G, Swierad M, Podolecki T, Marques J, Azevedo P, Pereira MA, Gaspar A, Monteiro S, Goncalves F, Leite L, Mimoso J, Manuel Lopes dos Santos W, Amado J, Pereira D, Silva B, Caires G, Neto M, Rodrigues R, Correia A, Freitas D, Lourenco A, Ferreira F, Sousa F, Portugues J, Calvo L, Almeida F, Alves M, Silva A, Caria R, Seixo F, Militaru C, Ionica E, Tatu-Chitoiu G, Istratoaie O, Florescu M, Lipnitckaia E, Osipova O, Konstantinov S, Bukatov V, Vinokur T, Egorova E, Nefedova E, Levashov S, Gorbunova A, Redkina M, Karaulovskaya N, Bijieva F, Babich N, Smirnova O, Filyanin R, Eseva S, Kutluev A, Chlopenova A, Shtanko A, Kuppar E, Shaekhmurzina E, Ibragimova M, Mullahmetova M, Chepisova M, Kuzminykh M, Betkaraeva M, Namitokov A, Khasanov N, Baleeva L, Galeeva Z, Magamedkerimova F, Ivantsov E, Tavlueva E, Kochergina A, Sedykh D, Kosmachova E, Skibitskiy V, Porodenko N, Namitokov A, Litovka K, Ulbasheva E, Niculina S, Petrova M, Harkov E, Tsybulskaya N, Lobanova A, Chernova A, Kuskaeva A, Kuskaev A, Ruda M, Zateyshchikov D, Gilarov M, Konstantinova E, Koroleva O, Averkova A, Zhukova N, Kalimullin D, Borovkova N, Tokareva A, Buyanova M, Khaisheva L, Pirozhenko A, Novikova T, Yakovlev A, Tyurina T, Lapshin K, Moroshkina N, Kiseleva M, Fedorova S, Krylova L, Duplyakov D, Semenova Y, Rusina A, Ryabov V, Syrkina A, Demianov S, Reitblat O, Artemchuk A, Efremova E, Makeeva E, Menzorov M, Shutov A, Klimova N, Shevchenko I, Elistratova O, Kostyuckova O, Islamov R, Budyak V, Ponomareva E, Ullah Jan U, Alshehri AM, Sedky E, Alsihati Z, Mimish L, Selem A, Malik A, Majeed O, Altnji I, AlShehri M, Aref A, AlHabib K, AlDosary M, Tayel S, Abd AlRahman M, Asfina KN, Abdin Hussein G, Butt M, Markovic Nikolic N, Obradovic S, Djenic N, Brajovic M, Davidovic A, Romanovic R, Novakovic V, Dekleva M, Spasic M, Dzudovic B, Jovic Z, Cvijanovic D, Veljkovic S, Ivanov I, Cankovic M, Jarakovic M, Kovacevic M, Trajkovic M, Mitov V, Jovic A, Hudec M, Gombasky M, Sumbal J, Bohm A, Baranova E, Kovar F, Samos M, Podoba J, Kurray P, Obona T, Remenarikova A, Kollarik B, Verebova D, Kardosova G, Studencan M, Alusik D, Macakova J, Kozlej M, Bayes-Genis A, Sionis A, Garcia Garcia C, Lidon RM, Duran Cambra A, Labata Salvador C, Rueda Sobella F, Sans Rosello J, Vila Perales M, Oliveras Vila T, Ferrer Massot M, Bañeras J, Lekuona I, Zugazabeitia G, Fernandez-Ortiz A, Viana Tejedor A, Ferrera C, Alvarez V, Diaz-Castro O, Agra-Bermejo RM, Gonzalez-Cambeiro C, Gonzalez-Babarro E, Domingo-Del Valle J, Royuela N, Burgos V, Canteli A, Castrillo C, Cobo M, Ruiz M, Abu-Assi E, Garcia Acuna JM. The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry. European Heart Journal - Quality of Care and Clinical Outcomes 2019; 6:100-104. [DOI: 10.1093/ehjqcco/qcz042] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 07/24/2019] [Indexed: 12/20/2022]
Abstract
Abstract
Aims
The Acute Cardiac Care Association (ACCA)–European Association of Percutaneous Coronary Intervention (EAPCI) Registry on ST-elevation myocardial infarction (STEMI) of the EurObservational programme (EORP) of the European Society of Cardiology (ESC) registry aimed to determine the current state of the use of reperfusion therapy in ESC member and ESC affiliated countries and the adherence to ESC STEMI guidelines in patients with STEMI.
Methods and results
Between 1 January 2015 and 31 March 2018, a total of 11 462 patients admitted with an initial diagnosis of STEMI according to the 2012 ESC STEMI guidelines were enrolled. Individual patient data were collected across 196 centres and 29 countries. Among the centres, there were 136 percutaneous coronary intervention centres and 91 with cardiac surgery on-site. The majority of centres (129/196) were part of a STEMI network. The main objective of this study was to describe the demographic, clinical, and angiographic characteristics of patients with STEMI. Other objectives include to assess management patterns and in particular the current use of reperfusion therapies and to evaluate how recommendations of most recent STEMI European guidelines regarding reperfusion therapies and adjunctive pharmacological and non-pharmacological treatments are adopted in clinical practice and how their application can impact on patients’ outcomes. Patients will be followed for 1 year after admission.
Conclusion
The ESC ACCA-EAPCI EORP ACS STEMI registry is an international registry of care and outcomes of patients hospitalized with STEMI. It will provide insights into the contemporary patient profile, management patterns, and 1-year outcome of patients with STEMI.
Collapse
Affiliation(s)
- Uwe Zeymer
- Hospital of the City of Ludwigshafen, Medical Clinic B and Institute of Heart Attack Research, Ludwigshafen on the Rhine, Germany
| | - Peter Ludman
- Institute of Cardiovascular Sciences, Birmingham University, Birmingham, UK
| | - Nicolas Danchin
- Cardiology Department, Georges Pompidou European Hospital, Paris, France
| | - Petr Kala
- Internal Cardiology Department, University Hospital Brno, Czech Republic
| | - Aldo P Maggioni
- EURObservational Research Programme, ESC, Sophia Antipolis, France
- ANMCO Research Center, Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Angelats L, Garcia Campelo M, Bernabe Caro R, Arriola Aperribay E, Calvo de Juan V, Barba Joaquín A, Vinolas Segarra N, Gil Moreno M, Vilà Martinez L, Juan Vidal O, Vilariño Quintela N, Cobo M, Sais E, Domine Gomez M, Fernandez Nuñez N, Coves Sarto J, Marse Fabregat R, Esteve Gomez A, Rodríguez-Abreu D, Carcereny Costa E. Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han J, Hida T, Moro-Sibilot D, Conkling P, Gandara D, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer 2019; 107:124-132. [DOI: 10.1016/j.ejca.2018.11.020] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 11/09/2018] [Indexed: 01/05/2023]
|
35
|
Rizvi N, Chul Cho B, Reinmuth N, Lee K, Ahn MJ, Luft A, van den Heuvel M, Cobo M, Smolin A, Vicente D, Moiseyenko V, Antonia S, Le Moulec S, Robinet G, Natale R, Nakagawa K, Zhao L, Stockman P, Chand V, Peters S. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy511.005] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Goss G, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Isla D, Morabito A, Min Y, Ardizzoni A, Cseh A, Bender S, Felip E. Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Felip E, Nishio M, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, SK Mok T, Scagliotti G, Spigel D, Passos V, Chen Z, Shaw A. Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.069] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Peters S, Danson S, Hasan B, Reinmuth N, Majem M, Tournoy K, Mark M, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Massutí B, Coate L, von Moos R, Zielinski C, De Maio E, O’Brien M, Roschitzki-Voser H, Dafni U, Stahel R. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Morgensztern D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Ong T. P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Barlesi F, Nishio M, Cobo M, Steele N, Paramonov V, Parente B, Dear R, Berard H, Peled N, Seneviratne L, Baldini E, Watanabe S, Goto K, Mendus D, Patel H, Deng Y, Kowanetz M, Hoang T, Lin W, Papadimitrakopoulou V. IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.066] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Talbot D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Morgensztern D, Ong T. P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Gray J, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee J, Pang Y, Cobo M, Kasahara K, Hodge R, Lentrichia B, Dearden S, Ramalingam S. OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.348] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Massuti B, Cobo M, Rodriguez-Paniagua M, Ballesteros I, Moran T, Arrabal R, Gonzalez Larriba J, Barneto I, Pun YW, de Castro Carpeño J, Ponce-Aix S, Baamonde C, Muñoz M, Lopez-Vivanco G, Rivas de Andres J, Isla D, Lopez R, Sanchez J, Sánchez-Payá J, Rosell R. PL 02.04 SCAT Ph III Trial: Adjuvant CT Based on BRCA1 Levels in NSCLC N+ Resected Patients. Final Survival Results a Spanish Lung Cancer Group Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.097] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Goss G, Felip E, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel S, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria J. P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1484] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
45
|
Vicent L, Gonzalez-Saldivar H, Bouza E, Munoz P, Cuerpo G, De Alarcon A, Vidal B, Cobo M, Goenaga M, Carrasco Chinchilla F, Montejo M, Galvez-Acebal J, Hidalgo-Tenorio M, Vinuesa-Garcia D, Martinez-Selles M. P4545Prognostic implications of a negative echocardiography in patients with infective endocarditis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
de Dios-Caballero J, Vida R, Cobo M, Máiz L, Suárez L, Galeano J, Baquero F, Cantón R, del Campo R. WS03.7 Coexistence of prey and predator bacteria in cystic fibrosis lung microbiota. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30174-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Gadgeel S, Soria J, Felip E, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Ardizzoni A, Dupuis N, Gibson N, Krämer N, Bühnemann C, Solca F, Ehrnrooth E, Goss G. Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30671-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Cocho D, Sagales M, Cobo M, Homs I, Serra J, Pou M, Perez G, Pujol G, Tantinya S, Bao P, Aloy A, Sabater R, Gendre J, Otermin P. Reducción de la tasa de broncoaspiración con el test 2 volúmenes/3 texturas con pulsioximetría en una unidad de ictus. Neurologia 2017; 32:22-28. [DOI: 10.1016/j.nrl.2014.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 11/15/2014] [Accepted: 12/02/2014] [Indexed: 10/24/2022] Open
|
49
|
Lee K, Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Goker E, Georgoulias V, Li W, Guclu S, Isla D, Ardizzoni A, Gadgeel S, Dupuis N, Gibson N, Krämer N, Bühnemann C, Solca F, Ehrnrooth E, Goss G. 446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J. A consensus statement on the gender perspective in lung cancer. Clin Transl Oncol 2016; 19:527-535. [PMID: 27885542 DOI: 10.1007/s12094-016-1578-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 11/12/2016] [Indexed: 10/20/2022]
Abstract
Lung cancer is the most common cancer globally and has the highest mortality. Although this disease is not associated with a particular gender, its incidence is rising among women, who are diagnosed at an increasingly younger age compared with men. One of the main reasons for this rise is women taking up smoking. However, many non-smoking women also develop this disease. Other risk factors implicated in the differential development of lung cancer in women are genetic predisposition, tumour histology and molecular profile. Proportionally more women than men with lung cancer have a mutation in the EGFR gene. This consensus statement reviews the available evidence about the epidemiological, biological, diagnostic, therapeutic, social and psychological aspects of lung cancer in women.
Collapse
Affiliation(s)
- D Isla
- Medical Oncology Department, Lozano Blesa Clinical University Hospital, Avda. San Juan Bosco 15, 50009, Zaragoza, Spain.
| | - M Majem
- Medical Oncology Department, Sant Pau University Hospital, Barcelona, Spain
| | - N Viñolas
- Medical Oncology Department, Clinic Hospital, Barcelona, Spain
| | - A Artal
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - A Blasco
- Medical Oncology Department, Valencia General University Hospital, Valencia, Spain
| | - E Felip
- Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - P Garrido
- Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
| | - J Remón
- Medical Oncology Department, Mataró University Hospital, Mataró, Barcelona, Spain
| | - M Baquedano
- Medical Oncology Department, Lozano Blesa Clinical University Hospital, Avda. San Juan Bosco 15, 50009, Zaragoza, Spain
| | - J M Borrás
- Scientific Coordinator of Cancer Strategy of the Spanish National Health System, University of Barcelona, Barcelona, Spain
| | - M Die Trill
- Atrium, Psyco-Oncology and Clinical Psychology, Madrid, Spain
| | - R García-Campelo
- Medical Oncology Department, A Coruña University Hospital, A Coruña, Spain
| | - O Juan
- Medical Oncology Department, La Fé University Hospital, Valencia, Spain
| | - C León
- Psyco-Oncology Unit, Terrassa Hospital and Parc Taulí University Hospital, Sabadell, Spain
| | - P Lianes
- Medical Oncology Department, Mataró University Hospital, Mataró, Barcelona, Spain
| | - F López-Ríos
- Targeted Therapies Laboratory, Department of Pathology, HM Sanchinarro University Hospital, Madrid, Spain
| | - L Molins
- Thoracic Surgery Department, Clinic Hospital, Barcelona, Spain
| | - M Á Planchuelo
- Humanization of Healthcare Department, Consejería de Sanidad, Madrid, Spain
| | - M Cobo
- Medical Oncology Department, Virgen de la Victoria University Hospital, Málaga, Spain
| | - L Paz-Ares
- Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain
| | - J M Trigo
- Medical Oncology Department, Virgen de la Victoria University Hospital, Málaga, Spain
| | - J de Castro
- Medical Oncology Department, La Paz University Hospital, Madrid, Spain
| |
Collapse
|